Overview

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.



Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.45
Change (%) Stock is Up 0.05 (0.68%)
Volume140,541
Data as of 09/28/16 2:28 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
09/22/16T2 Biosystems Announces $40 Million Equity Investment by Partner Canon U.S.A.
Canon U.S.A. takes 19.9 percent stake in the company; Seymour Liebman joins board of directors       LEXINGTON, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the purchase by Canon U.S.A., of approximately $40 million of the company’s stock in a private placement. The shares were purchased at $6.56, the closing market price of Tuesday, September 20, 2016. With this inve... 
Printer Friendly Version
09/21/16T2 Biosystems Presents Data on the Company’s T2MR® Technology for the Detection of the Bacteria that Causes Lyme Disease Directly from Whole Blood at Cold Spring Harbor Laboratory Conference on Diagnostic Tests for Lyme Disease
LEXINGTON, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, announced that Tom Lowery, Ph.D., chief scientific officer, today presented data on the T2 Magnetic Resonance (T2MR®) technology for the detection of Borrelia – the bacteria that causes Lyme disease – directly from whole blood samples. The data were presented at the Diagnostic Tests for Lyme Disease Conference at the Banbury Cent... 
Printer Friendly Version
09/01/16T2 Biosystems to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the following upcoming investor conferences in New York City: The NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 11:00 a.m. ET. The Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016, at 2:... 
Printer Friendly Version
08/04/16T2 Biosystems to Present at the Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016, at 8:30 a.m. ET in Boston. A live, listen-only webcast of the presentation may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at ww... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646
Data provided by Nasdaq. Minimum 15 minutes delayed.